Posted by Michael Wonder on 29 Jan 2017
Sunovion’s Latuda (lurasidone hydrochloride) receives FDA approval to treat adolescents with schizophrenia
28 January 2017 - First treatment approved in five years for adolescents aged 13-17 years with schizophrenia.
Sunovion Pharmaceuticals today announced that the U.S. FDA approved the supplemental new drug application for Latuda (lurasidone hydrochloride) for the treatment of schizophrenia in adolescents aged 13 to 17 years.
Latuda is also approved in the U.S. for the treatment of adults with schizophrenia and for the treatment of adults with major depressive episodes associated with bipolar I disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.
